Contrarian Investment Strategies for Retirement: A Detailed Review of Envista, MSG Entertainment, and Smucker
Money

Contrarian Investment Strategies for Retirement: A Detailed Review of Envista, MSG Entertainment, and Smucker

authorBy Mr. Money Mustache
DateJun 30, 2026
Read Time3 min

John Rogers, a respected figure in investment circles, champions a long-term, value-oriented approach, seeking out undervalued small and mid-cap companies. His strategy involves identifying resilient businesses with strong brand identities that are temporarily out of favor, holding them through periods of market skepticism until their true worth is recognized. However, not every such contrarian opportunity fits the specific requirements of a retiree, who typically prioritizes stable income, predictable performance, and minimal market volatility. This article examines three companies—Envista, MSG Entertainment, and J.M. Smucker—to determine their appropriateness for a retirement portfolio, ranking them by their alignment with these critical retiree investment objectives.

Among the three, Envista stands out as the archetypal contrarian bet, yet it is least suitable for retirees. This dental products manufacturer, known for brands like Nobel Biocare and Ormco, has underperformed significantly over several years. While its operational recovery is showing promise, with robust Q1 FY2026 results including a 14.4% year-over-year revenue increase and a 25% rise in adjusted EBITDA, it lacks a crucial element for retirement investors: a dividend. Trading at a high trailing P/E of approximately 66x and possessing the highest beta among the reviewed companies at 0.886, Envista's risk profile makes it a challenging choice for those seeking stability. Similarly, MSG Entertainment, with its portfolio of iconic venues such as Madison Square Garden and Radio City Music Hall, presents a compelling picture of a durable franchise. Despite its impressive stock performance over the past year and strong demand for its entertainment offerings, the company, like Envista, does not offer a dividend. Its reliance on discretionary consumer spending and a high trailing P/E of 79x also diminish its appeal for a conservative retirement strategy. Both companies, while embodying the contrarian spirit, are more suited for growth-oriented portfolios rather than those focused on income generation and risk aversion.

J.M. Smucker emerges as the most fitting option for retirement investors. With a diverse array of household brands like Folgers, Jif, and Milk-Bone, Smucker operates as a consumer staples and pet food powerhouse. Despite recent market skepticism following its acquisition of Hostess, the company's Q4 FY2026 results were strong, with adjusted EPS surpassing expectations and free cash flow experiencing a significant surge of 61.9% to $483.9 million. For retirees, Smucker's income proposition is particularly attractive. It offers a consistent annual dividend of $4.40, translating to a 3.8% yield, supported by over 27 consecutive years of quarterly dividend payments and regular increases. Its low beta of just 0.264 and a forward P/E of 12x underscore its stability and value. While there are risks, such as a slight decline in Sweet Baked Snacks sales and past Hostess impairments, the company's reliable dividend, low volatility, and consistent demand for its essential products make it an ideal choice for a retirement portfolio. Smucker exemplifies how a truly patient, value-driven investment strategy can align with the needs of those seeking both long-term growth and immediate income in their golden years.

Ultimately, John Rogers' investment philosophy of identifying and holding temporarily undervalued assets can indeed be beneficial, but its application must be tailored to the specific needs of an investor. For retirees, the emphasis shifts from pure growth to a combination of capital preservation, consistent income, and low volatility. While Envista and MSG Entertainment offer potential for appreciation, their lack of dividends and higher risk profiles make them less suitable for retirement portfolios. J.M. Smucker, however, with its robust dividend, established market position, and resilience in consumer demand, perfectly illustrates how a contrarian investment can also provide the stability and income crucial for a secure retirement. This demonstrates that sound investment principles, when applied thoughtfully, can lead to positive and secure financial outcomes, ensuring that diligence and patience are rewarded.

More Articles
Money
Cooke Acquires Mowi's East Canadian Salmon Farms
Cooke, a prominent seafood company, has entered an agreement to acquire Mowi's salmon farming operations in Eastern Canada for C$225 million. This strategic acquisition will enable Mowi to sharpen its focus on core farming regions while providing Cooke with significant growth opportunities in Atlantic Canada, including hatchery facilities, sea farms, and processing plants. The deal, expected to finalize in the latter half of the year, underscores a dynamic period of consolidation and strategic realignment within the global salmon industry.
By Mr. Money MustacheJun 30, 2026
Money
German Beverage Industry Opposes Proposed Sugar Tax
Over 300 German beverage companies and industry associations have collectively voiced strong opposition to the government's proposed sugar tax, slated for implementation in 2028. They argue the tax, intended to curb rising healthcare costs, lacks scientific justification, would disproportionately burden consumers and businesses during challenging economic times, and could destabilize the market without effectively addressing public health concerns.
By Natalie PaceJun 30, 2026
Money
Akebia Therapeutics Reinforces Vafseo Patent Portfolio
Akebia Therapeutics has significantly bolstered the intellectual property protection for its key therapeutic, Vafseo (vadadustat), extending its patent coverage through 2036. This strategic move, driven by a new FDA Orange Book listing and a five-year extension for a core patent, enhances the long-term commercial viability of the kidney disease treatment. The company also reported strong Q1 2026 financial results, with Vafseo product revenue reaching $15.8 million and a substantial increase in patient usage and prescribers.
By Natalie PaceJun 30, 2026
Money
Syndax Pharmaceuticals: A Biotech Opportunity Amidst Evolving AML Market Dynamics
Syndax Pharmaceuticals (SNDX) continues to be a promising biotech investment, despite a recent reduction in its price target by Guggenheim due to revised Acute Myeloid Leukemia (AML) market estimates. The company recently published positive Phase 1/2 SAVE trial results for its oral combination regimen (Revuforj, decitabine/cedazuridine, and venetoclax) in relapsed or refractory AML patients, demonstrating an 88% overall response rate. This underscores Syndax's potential in hematologic malignancies.
By Scott PapeJun 30, 2026
Money
MapLight Therapeutics: A Biotech Stock to Watch
MapLight Therapeutics (MPLT) is gaining attention as a promising biotech company, particularly with its advancements in treating schizophrenia and Alzheimer's disease. Raymond James initiated coverage with a "Strong Buy" rating, anticipating positive results from the upcoming ZEPHYR trial for ML-007C-MA. The company also reported clinically meaningful improvements in irritability for adolescents with autism spectrum disorder in its Phase 2 IRIS trial. MPLT focuses on central nervous system disorders using innovative neurotechnologies.
By JL CollinsJun 30, 2026